Innate Pharma SA (OTCMKTS:IPHYF – Get Free Report)’s share price traded up 9.3% during trading on Tuesday . The company traded as high as $1.50 and last traded at $1.50. 1,000 shares traded hands during trading, an increase of 19,900% from the average session volume of 5 shares. The stock had previously closed at $1.3725.
Innate Pharma Stock Performance
The stock has a 50-day moving average price of $1.88 and a 200 day moving average price of $1.99.
About Innate Pharma
Innate Pharma is a clinical-stage biotechnology company headquartered in Marseille, France, focused on harnessing the innate immune system to develop novel immunotherapies for oncology and inflammatory diseases. Founded in 1999, the company applies its expertise in natural killer (NK) cell and macrophage biology to design antibodies and other biologic agents that modulate immune checkpoints and enhance antitumor responses.
The company’s pipeline includes several lead programs such as monalizumab, an anti-NKG2A antibody designed to restore NK cell and CD8+ T cell activity, and lirilumab, which targets KIR receptors on NK cells to promote tumor cell killing.
Read More
Receive News & Ratings for Innate Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innate Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
